



**GORE® CARDIOFORM**  
ASD Occluder

YOUR ASD TOOLKIT  
JUST GOT BIGGER




*Together, improving life*

# The new GORE® CARDIOFORM ASD Occluder lets you extend confident closure to more patients than ever

## Anatomically adaptable waist

- Fills and conforms to the defect for atrial septal defects (ASDs) from 8 to 35 mm<sup>1</sup>
- Soft and conformable construction designed to integrate with the natural structure of the atrial septum
- Device design and material properties combine to optimize septal conformability and tissue ingrowth for short and long term performance



## Confident closure

### Gore ASSURED Clinical Study 6-month data

**Clinicians at 20 sites enrolled 125 patients and experienced high technical success and 100% closure success rate at 6 months<sup>\*,2</sup>**

|                                       |                  |
|---------------------------------------|------------------|
| Technical success rate <sup>1,2</sup> | 96% (120 / 125)  |
| Closure success rate <sup>*,2</sup>   | 100% (112 / 112) |

- No retro-aortic rim required — closure success with retro-aortic rim lengths of 0 to 27 mm (median of 4 mm)<sup>2</sup>
- 57% of patients had a deficient retro-aortic rim (< 5 mm)<sup>4</sup>
- Repositionable and retrievable technology helps ensure proper device positioning

**100%** closure success rate  
at 6 months<sup>\*,2</sup>

## Proven safety

Designed in partnership with leading interventional cardiologists across the globe, the GORE® CARDIOFORM ASD Occluder builds on a legacy of safety.

### Low rate of 30-day SAEs<sup>2</sup>

The GORE® CARDIOFORM ASD Occluder is an extension of a family of occluders that has demonstrated no history of erosion.<sup>2,3</sup>

| Attempted closure            | Subjects (N = 125) |
|------------------------------|--------------------|
| 30-day SAEs <sup>2</sup>     | 6 (4.8%)           |
| Supraventricular tachycardia | 1 (0.8%)           |
| Cerebrovascular accident     | 1 (0.8%)           |
| Device embolization          | 1 (0.8%)           |
| Fever                        | 1 (0.8%)           |
| Atrial fibrillation          | 1 (0.8%)           |
| Migraine with aura           | 1 (0.8%)           |

### Low rate of clinically significant new arrhythmia<sup>‡,2</sup>

### Low rate of device events<sup>||,2</sup>

| Attempted closure                                    | Subjects (N = 125) |
|--|--------------------|
| Clinically significant new arrhythmia <sup>‡,2</sup> | 6 (4.8%)           |
| Device events <sup>  ,2</sup>                        | 3 (2.4%)           |

# Extending what you can achieve with the GORE® CARDIOFORM Occluder family

With the conformable design of the GORE® CARDIOFORM family, eight catalogue numbers cover ASDs up to 35 mm.<sup>5</sup>

## GORE® CARDIOFORM ASD Occluder

| Catalogue number | Treatment range measured with stop flow balloon sizing | Catheter size <sup>6</sup> |
|------------------|--|----------------------------|
| ASD27E           | 8–15 mm  | 10 Fr                      |
| ASD32E           | 13–20 mm   | 10 Fr                      |
| ASD37E           | 18–25 mm   | 11 Fr                      |
| ASD44E           | 23–30 mm   | 12 Fr                      |
| ASD48E           | 28–35 mm   | 14 Fr                      |



## GORE® CARDIOFORM Septal Occluder

| Catalogue number | Maximum recommended defect size (Stop flow balloon sizing) | Catheter size |
|------------------|--|---------------|
| GSXE0020         | 11 mm  | 10 Fr         |
| GSXE0025         | 14 mm  | 10 Fr         |
| GSXE0030         | 17 mm  | 10 Fr         |



Ask your Gore sales associate about opportunities to train on the GORE® CARDIOFORM ASD Occluder.



## References

1. GORE® CARDIOFORM ASD Occluder Imaging Training Tool. Flagstaff, AZ. W. L. Gore & Associates; 2017. [Digital training tool]. AW0214-EN1.
2. GORE® CARDIOFORM ASD Occluder [*Instructions for Use*]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2019.
3. Søndergaard L, Kasner SE, Rhodes JF, et al; Gore REDUCE Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. *New England Journal of Medicine* 2017;377(11):1033-1042.
4. Gore ASSURED Clinical Study.
  - \* Defined as a clinical residual defect status of occluded or clinically insignificant as determined by the Echo Core Lab at the 6-month evaluation among subjects with technical success.
  - † Successful deployment and retention (at conclusion of index procedure) of a GORE® CARDIOFORM ASD Occluder.
  - ‡ In subjects without prior history of arrhythmia, any new arrhythmia (documented on ECG) requiring hospitalization, initiation of new long-term medical therapy (persisting > 45 days), or any post-index procedure cardioversion or intervention (pacemaker, ablation, etc.)
  - § The GORE® CARDIOFORM ASD Occluder is only indicated for the percutaneous, transcatheter closure of ostium secundum atrial septal defects (ASDs).
  - || Defined as post-procedure embolization, device removal, or other device reintervention from completion of the implant procedure through 6 months (180 days) post-procedure.
  - ¶ If a 0.035" guidewire is used it is recommended to increase the introducer sheath size by 2 Fr.

Products listed may not be available in all markets.

GORE, *Together, improving life*, CARDIOFORM and designs are trademarks of W. L. Gore & Associates, Inc.  
©2019 W. L. Gore & Associates GmbH OCTOBER 2019

---

**W. L. Gore & Associates, Inc.**  
Flagstaff, AZ 86004  
+65.67332882 (Asia Pacific) 800.437.8181 (United States)  
00800.6334.4673 (Europe) 928.779.2771 (United States) [goremedical.com](http://goremedical.com)

